Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Receivables (2016 - 2025)

Vanda Pharmaceuticals' Receivables history spans 16 years, with the latest figure at $54.6 million for Q4 2025.

  • For Q4 2025, Receivables rose 15.87% year-over-year to $54.6 million; the TTM value through Dec 2025 reached $54.6 million, up 15.87%, while the annual FY2025 figure was $54.6 million, 15.87% up from the prior year.
  • Receivables for Q4 2025 was $54.6 million at Vanda Pharmaceuticals, up from $50.5 million in the prior quarter.
  • Across five years, Receivables topped out at $54.6 million in Q4 2025 and bottomed at $24.5 million in Q1 2023.
  • The 5-year median for Receivables is $35.4 million (2023), against an average of $37.5 million.
  • The largest annual shift saw Receivables skyrocketed 50.85% in 2021 before it decreased 29.27% in 2022.
  • A 5-year view of Receivables shows it stood at $32.5 million in 2021, then rose by 3.22% to $33.5 million in 2022, then grew by 1.92% to $34.2 million in 2023, then skyrocketed by 37.9% to $47.1 million in 2024, then rose by 15.87% to $54.6 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Receivables are $54.6 million (Q4 2025), $50.5 million (Q3 2025), and $45.0 million (Q2 2025).